Barclays initiated coverage of Repligen (RGEN) with an Overweight rating and $150 price target The firm says that as a bioprocessing pure-play, it likes Repligen’s positioning in the current macro tape. Bioprocessing continues to be Barclays’ most preferred subsector given its relative insulation from the major macro headwinds impacting tools, and Repligen is a particularly attractive asset given its heavier weighting towards the clinic, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Regeneron Stock (REGN) Retreats as Lung Disease Drug Data Disappoints
- Repligen Holds Annual Shareholders Meeting, Key Decisions Made
- Repligen’s Strategic Growth and Resilience Drive Buy Rating with $180 Price Target
- Repligen’s Strong Market Position and Growth Potential Justify Buy Rating Amid Minimal Tariff Exposure
- Repligen price target lowered to $189 from $202 at RBC Capital